浏览全部资源
扫码关注微信
Mibefradil通过下调FoxO1表达改善HepG2细胞的胰岛素抵抗
Mibefradil improves insulin-resistance HepG2 cells by down-regulating FoxO1 expression
- 第三军医大学学报 2017年39卷第20期 页码：1973-1979
- 作者机构：
1.400037 重庆, 第三军医大学新桥医院: 内分泌科
2.400042 重庆, 第三军医大学大坪医院野战外科研究所第一研究室, 创伤、烧伤与复合伤国家重点实验室
3.400037 重庆, 第三军医大学新桥医院: 中心实验室
4.400037 重庆, 第三军医大学新桥医院: 中西医结合科
- 作者简介：
[徐梓辉, E-mail: zihuixu@yeah.net XU Zihui, E-mail: zihuixu@yeah.net
- 基金信息：国家自然科学基金面上项目(81570781)
DOI：10.16016/j.1000-5404.201705074
中图分类号： R458.5;R735.7;R977.15收稿：2017-06-01，
修回：2017-07-18，
纸质出版：2017-10-30
- 稿件说明：
移动端阅览
马欢, 严军, 张克斌, 等. Mibefradil通过下调FoxO1表达改善HepG2细胞的胰岛素抵抗[J]. 第三军医大学学报, 2017,39(20):1973-1979.
Huan MA, Jun YAN, Kebin ZHANG, et al. Mibefradil improves insulin-resistance HepG2 cells by down-regulating FoxO1 expression[J]. Journal of Third Military Medical University, 2017, 39(20): 1973-1979.
马欢, 严军, 张克斌, 等. Mibefradil通过下调FoxO1表达改善HepG2细胞的胰岛素抵抗[J]. 第三军医大学学报, 2017,39(20):1973-1979. DOI： 10.16016/j.1000-5404.201705074.
Huan MA, Jun YAN, Kebin ZHANG, et al. Mibefradil improves insulin-resistance HepG2 cells by down-regulating FoxO1 expression[J]. Journal of Third Military Medical University, 2017, 39(20): 1973-1979. DOI： 10.16016/j.1000-5404.201705074.
摘要
目的
2
探索Mibefradil在体外对胰岛素抵抗HepG2细胞的作用。
方法
2
将HepG2细胞分为对照组、棕榈酸盐(Palmitate，PA)诱导的HepG2细胞胰岛素抵抗模型组、药物溶剂(DMSO)组、低剂量(0.025 μmol/L)Mibefradil组、高剂量(0.05 μmol/L)Mibefradil组，通过检测各组糖原合成及葡萄糖消耗，观察Mibefradil对胰岛素抵抗HepG2细胞的改善作用。用qRT-PCR、Western blot检测各组FoxO1，糖异生、糖原分解限速酶，即：磷酸烯醇式丙酮酸羧基激酶(PEPCK)、葡萄糖-6-磷酸激酶(G6Pase)的mRNA、蛋白相对表达量，明确转录因子FoxO1及其靶基因的表达水平。
结果
2
相比于对照组，HepG2细胞胰岛素抵抗模型组的糖原合成量[(3.28±0.74) μg/μL
vs
(9.14±0.33) μg/μL，
P
<
0.01
]
及葡萄糖消耗量[(1.31±0.49) nmol/μg
vs
(5.87±2.26) nmol/μg，
P
<
0.01
]
明显下降；经Mibefradil干预后，胰岛素抵抗HepG2细胞的糖原合成及葡萄糖消耗得到明显改善，且高剂量组的糖原合成[(7.0
9±0.60) μg/μL
vs
(5.73±0.16) μg/μL，
P
<
0.01)
]
及葡萄糖消耗[(6.45±0.02) nmol/μg
vs
(5.61±0.29) nmol/μg，
P
<
0.01
]
显著高于低剂量组，表明Mibefradil可改善HepG2细胞的胰岛素抵抗。qRT-PCR及Western blot检测结果表明，胰岛素抵抗HepG2细胞的FoxO1、PEPCK、G6Pase的表达量均显著增加(
P
<
0.01)；经Mibefradil干预后，其表达量呈剂量依赖性下降(
P
<
0.05)。
结论
2
Mibefradil对胰岛素抵抗HepG2细胞具有改善作用，此作用可能与下调FoxO1的表达有关。
Abstract
Objective
2
To explore the ameliorative effect of Mibefradil on the insulin resistance model of HepG2 cells
in vitro
.
Methods
2
HepG2 cells were randomly divided into 5 groups
that is
control group
insulin resistance model group (induced by 0.25 mmol/L palmitate)
DMSO model group
low-dosage Mibefradil treatment group (0.025 μmol/L)
and high-dosage Mibefradil treatment group (0.05 μmol/L). And all groups were disposed with corresponding drugs according to the above mentioned for 24 h. Glycogen synthesis and glucose consumption of HepG2 cells of each group were detected to observe treatment effects of Mibefradil. Quantitative real-time PCR (qRT-PCR) and Western blotting were used to detect the expression levels of FoxO1 and limited enzymes of gluconeogenesis and glycogenolysis
that is
phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase)
which are the target genes of FoxO1.
Results
2
Compared with control group
the model group had significantly decreased glycogen synthesis (3.28± 0.74
vs
9.14±0.33 μg/μL
P
<
0.01) and glucose consumption (1.31±0.49
vs
5.87±2.26 nmol/μg
P
<
0.01). Mibefradil treatment obviously improved glycogen synthesis and glucose consumption in the HepG2 cells of insulin resistance model
with the high-dosage Mibefradil group more significant than the low-dosage
one (7.09±0.60
vs
5.73±0.16 μg/μL
P
<
0.01; 6.45±0.02
vs
5.61±0.29 nmol/μg
P
<
0.01). qRT-PCR and Western blotting indicated that the expression levels of FoxO1
PEPCK and G6Pase were remarkably increased in the HepG2 cells of insulin resistance model
however Mibefradil treatment would decrease the levels in a dose-dependent manner (
P
<
0.05).
Conclusion
2
Mibefradil relieves the insulin resistance of HepG2 cells
via
decreasing the expression of FoxO1.
关键词
Keywords
references
PEREZ-REYES E. Molecular physiology of low-voltage-activated T-type calcium channels[J]. Physiol Rev, 2003, 83(1): 117-161. DOI: 10.1152/physrev.00018.2002.
MASSIE B M.Mibefradil: a selective T-type calcium antagonist[J]. Am J Cardiol, 1997, 80(9A): 231-321. DOI: 10.1016/S0002-9149(97)00791-1.
IMOTO K, KUMATANI S, OKADA M. Endostatin is protective against monocrotaline-induced right heart disease through the inhibition of T-type Ca 2+ channel[J ] . Pflügers Arch, 2016, 468 (7): 1-12. DOI: 10.1007/s00424-016-1810-0.
LU Y, LONG M, ZHOU S, et al. Mibefradil reduces blood glucose concentration in db/db mice[J]. Clinics, 2014, 69(1): 61-67. DOI: 10.6061/clinics/2014(01)09.
LIU T Y, SHI C X, GAO R, et al. Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Aktpathway in type 2 diabetic mice and hepatocytes[J]. Cli Sci(Lond), 2015, 129(10): 839-850. DOI: 10.1042/CS20150009.
WEI S N, ZHANG M, YU Y, et al. Berberine attenuates development of the hepatic gluconeogenesis and lipid metabolism disorder in type 2 diabetic mice and in palmitate-incubated HepG2 cells through suppression of the HNF-4ɑ miR122[J]. PLoS ONE, 2016, 11(3): e0152097. DOI: 10.1371/journal.pone.0152097.
OH K J, HAN H S, KIM M J, et al.Transcriptional regulators of hepatic gluconeogenesis[J]. Arch Pharm Res, 2013, 36(2): 189-200. DOI: 10.1007/s12272-013-0018-5.
YADAV H, DEVALARAJA S, CHUNG ST, et al. TGF-β1/Smad3 pathway targets PP2A-AMPK-FoxO1 to regulate hepatic gluconeogenesis[J]. J Biol Chem, 2017, 292(8): 3420-3432. DOI: 10.1074/jbc.M116.764910.
GUO S. Molecular basis of insulin resistance: The role of IRS and foxo1 in the control of diabetes mellitus and its complications[J]. Drug Discov Today Dis Mech, 2013, 10(1-2): e27-e33. DOI: 10.1016/j.ddmec.2013.06.003.
RAJAN M R, NYMAN E, KJØLHEDE P, et al. systems-wide experimental and modeling analysis of insulin signaling through forkhead box protein O1 (FOXO1) in human adipocytes, Normally and in type 2 diabetes[J]. JBC, 2016, 291(30): 15806-15819. DOI: 10.1074/jbc.M116.715763.
ZHU X, WU Y B, ZHOU J, et al. Upregulation of lncRNA MEG3 promotes hepatic insulin resistance via increasing FoxO1 expression[J ] . Biochem Biophys Res Commun, 2016, 469(2): 319-325. DOI: 10.1016/j.bbrc.2015.11.048.
ZHANG K, LI L, QI Y, et al. Hepatic suppression of Foxo1 and Foxo3 causes hypoglycemia and hyperlipidemia in mice[J]. Endocrinology, 2012, 153(2): 631-646. DOI: 10.1210/en.2011-1527.
HAEUSLER, R A, KAESTNER K H, ACCILI D. FoxOs function synergistically to promote glucose production[J].J Biol Chem, 2010, 285(46): 35245-35248. DOI: 10.1074/jbc.C110.175851.
ALTOMONTE J, RICHTER A, HARBARAN S, et al.Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice[J]. Am J Physiol Endocrinol Metab, 2003, 285(4): E718-E728. DOI: 10.1152/ajpendo.00156.2003.
BHATTACHARJEE A, WHITEHURST R M J R, ZHANG M, et al. T-type calcium channels facilitate insulin secretion by enhancing general excitability in the insulin-secreting beta-cell line, INS-1[J]. Endocrinology, 1997, 138(9): 3735-3740. DOI: 10.1210/endo.138.9.5390.
游成姗, 严军, 李明, 等. Mibefradil抑制高糖诱导的胰岛素分泌作用及其机制的初步研究[J].第三军医大学学报, 2015, 37(7): 660-665. DOI: 10.16016/j.1000-5404.201410175.
YOU C S, YAN J, LI M, et al. Mibefradil suppresses insulin secretion of high glucose-induced islet cells by down-regulating cav3.1 and cav3.2[J]. J Third Mil Med Univ, 2015, 37(7): 660-665. DOI: 10.16016/j.1000-5404.201410175.
MILARDI D, SIACCA M F, RANDAZZO L, et al. The Role of Calcium, Lipid Membranes and Islet Amyloid Polypeptide in the Onset of Type 2 Diabetes: Innocent Bystanders or Partners in a Crime?[J]. Front Endocrinol, 2014, 5(5): 216. DOI: 10.3389/fendo.2014.00216.
OZCAN L, WONG C C, LI G, et al. Calcium signaling through CaMKⅡ regulates hepatic glucose production in fasting and obesity[J]. Cell Metab, 2012, 15(5): 739-751. DOI: 10.1016/j.cmet.2012.03.002.
0
浏览量
0
下载量
0
CSCD
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
